Illinois HB 4900 would empower the AG to deem when a generic pharmaceutical’s price increase is excessive. Not only has this approach been deemed unconstitutional (see Maryland’s experience), as EconoSTATS Managing Editor Wayne Winegarden argues, these proposals will harm patients and, ironically, worsen pharmaceutical affordability and innovation. You can read his editorial here.

Leave a Reply

Your email address will not be published. Required fields are marked *